Skip to main content

Generics

  • Dr. Reddy’s looks to branded generics to drive growth
    HYDERABAD, India — In his message to shareholders in the company’s 2015-2016 annual report, Dr. Reddy’s Laboratories chairman K Satish Reddy mentioned a new effort the company would be undertaking in North America — a branded generics platform. In addition to leveraging a pipeline of complex generics across its markets while focusing on OTC, Reddy said the branded generics would be one of the ways the company drives growth in the coming years. 
     

  • Report: FDA panel backs Amgen’s Humira biosimilar

  • Nichi-Iko to acquire Sagent Pharmaceuticals
    TOKYO AND SCHAUMBURG, Ill. — Japanese generic drug giant Nichi-Iko will be acquiring Sagent Pharmaceuticals, the two companies announced Tuesday. The $736 million all-cash transaction will see Nichi-Iko paying about a 40% premium on the closing price of the company’s shares at closing on July 8. 
     

  • FDA makes big progress on GDUFA backlog
    SILVER SPRING, Md. — The Food and Drug Administration’s Center for Drug Evaluation and Research has achieved its goal of clearing some of the backlog under the Generic Drug User Fee Agreement, according to an email sent by CDER director Janet Woodcock. 
     

  • Mylan launches generic Fenoglide
    PITTSBURGH — Mylan on Wednesday announced the launch of its generic og Fenoglide (fenofibrate) tablets. The drug is indicated to treat high LDL cholesterol, total cholesterol, triglycerides and apolipoprotein B as an adjunct to diet in adults with hypercholesterolemia or mixed dyslipidemia. 
     
    Mylan’s fenofibrate tablets will be available in 40- and 120-mg dosage strengths. The product had a total of $28.6 million for the 12 months ended April 30, according to IMS Health.  
     

  • Jean Coutu sees generics slow Q1 Rx retail sales growth
    VARENNES, Quebec — Canada’s Jean Coutu group on Tuesday released the sales and earnings figures from its FY2017 first quarter, which ended May 28. For the quarter, the company saw revenues of $723.6 million — a 1.6% rise over the same quarter last year. The company attributes its sales growth to overall market growth and the expansion of its franchised store network. 
     

  • NACDS, NCPA push Congress not to raise TRICARE copays
    WASHINGTON — Two industry organizations are asking Congress not to raise pharmacy copays for TRICARE beneficiaries. In a letter to the House and Senate Armed Services Committees, the National Association of Chain Drug Stores and National Community Pharmacists Association point out that the Congressional Budget Office has warned of the potential impact that provisions in the Senate FY2017 National Defense Authorization Act (NDAA). 
     

  • PhRMA taps Brian Toohey to head international advocacy
    WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Thursday announced the addition of Brian Toohey as SVP international advocacy, effective July 11. 
     
    Toohey is the former president and CEO of the Semiconductor Industry Association, where he oversaw that industry’s federal advocacy, international trade and technology programs. Before joining the SIA, Toohey had been at PhRMA, first as a lead international lobbyist and then as the leader of its international advocacy team. 
     
X
This ad will auto-close in 10 seconds